Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection

Trial Profile

A prospective, single-center investigator-initiated study of Mavrilimumab for the treatment of patients COVID-19 infection

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2020

At a glance

  • Drugs Mavrilimumab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2020 New trial record
    • 31 Mar 2020 According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6).

Trial Overview

Purpose

The primary objective investigator-initiated trial will be prevention of respiratory failure in patients with COVID-19 infections.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Organisations

  • Affiliations Kiniksa Pharmaceuticals

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Italy
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
MavrilimumabPrimary Drug Intravenous
-

Trial History

Event Date Event Type Comment
07 Apr 2020 New trial record New trial record Updated 07 Apr 2020
31 Mar 2020 Other trial event According to a Kiniksa Pharmaceuticals media release, Professor Lorenzo Dagna, MD, FACP (Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy) plans to initiate a prospective, single-center investigator-initiated study of Mavrilimumab, based on the initial results from the treatment protocol (n=6). Updated 07 Apr 2020

References

  1. Kiniksa Pharmaceuticals. Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation. Media-Rel 2020;.

    Media Release
Back to top